Key Highlights
- Alumis announced that its Phase 2b LUMUS trial of envudeucitinib for moderate-to-severe SLE failed to meet its primary and secondary endpoints.
- The miss occurred across the general participant population.
- The company highlighted dose-dependent interferon engagement and favorable responses in a prespecified IFNGS-high subgroup.
- Alumis maintains its Q4 2026 timeline for a psoriasis NDA submission.
Alumis Inc. (NASDAQ: ALMS) announced that its Phase 2b LUMUS trial of envudeucitinib for moderate-to-severe systemic lupus erythematosus failed to meet its primary and secondary endpoints across the general participant population.
What Happened
Despite the miss, the company highlighted dose-dependent interferon engagement and favorable responses in a prespecified IFNGS-high subgroup to support future Phase 3 regulatory dialogues, while maintaining its Q4 2026 timeline for a psoriasis NDA submission.
Market Reaction
The disclosed information does not include stock price or trading data for Alumis following the trial results.
Outlook
Future regulatory dialogues regarding a potential Phase 3 path in the IFNGS-high subgroup, alongside the planned Q4 2026 psoriasis NDA submission, represent the next disclosed milestones for Alumis.
FAQs
Q: Did Alumis' LUMUS trial meet its endpoints?
A: No, the Phase 2b trial failed to meet its primary and secondary endpoints in the general SLE population.
Q: Was there any positive signal in the data?
A: Yes, dose-dependent interferon engagement and favorable responses were seen in a prespecified IFNGS-high subgroup.
Q: What other program is Alumis advancing?
A: A psoriasis NDA submission, still targeted for Q4 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.